Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia

NCT01207440 is registered in ClinicalTrials.gov with Ariad Pharmaceuticals as lead sponsor.

NCT NCT01207440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01207440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
Lead sponsor
Ariad Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
January 17, 2019
Enrollment
449 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, ph+ acute lymphoblastic leukemia